LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.

• Suzhou Novartis Technical Development Co., Ltd.
• Novartis Pharmaceuticals (China) Suzhou Operations
• Novartis Pharma AG

• Intermediate

1. biocatalysis
2. chemocatalysis
3. heart failure
4. Intermediate
5. LCZ696
6. Research Article